How do you manage psoriatic arthritis in patients who are planning to start treatment with checkpoint inhibitors for underlying malignancy?  

This is a very important question, and I think rheumatologists will encounter cases like this more frequently as immune checkpoint inhibitors (ICIs) are being increasingly used. Roughly, 50% of patients with co-existing autoimmune disorders and malignancies have flare-ups of their autoimmune disorde...

Agree with Dr. @Sang Kim’s answer. Holding immunosuppressants at the start of immunotherapy when possible is advised to give the chance for the best tumor response then close follow-up as the incidence of flares is high.